標(biāo)題: Titlebook: RNA Vaccines; Methods and Protocol Thomas Kramps,Knut Elbers Book 2017 Springer Science+Business Media New York 2017 recombinant viruses.se [打印本頁] 作者: 惡夢 時(shí)間: 2025-3-21 18:20
書目名稱RNA Vaccines影響因子(影響力)
書目名稱RNA Vaccines影響因子(影響力)學(xué)科排名
書目名稱RNA Vaccines網(wǎng)絡(luò)公開度
書目名稱RNA Vaccines網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱RNA Vaccines被引頻次
書目名稱RNA Vaccines被引頻次學(xué)科排名
書目名稱RNA Vaccines年度引用
書目名稱RNA Vaccines年度引用學(xué)科排名
書目名稱RNA Vaccines讀者反饋
書目名稱RNA Vaccines讀者反饋學(xué)科排名
作者: compassion 時(shí)間: 2025-3-21 21:53 作者: collagen 時(shí)間: 2025-3-22 00:47
Methods in Molecular Biologyhttp://image.papertrans.cn/r/image/820208.jpg作者: 大猩猩 時(shí)間: 2025-3-22 04:41 作者: 怕失去錢 時(shí)間: 2025-3-22 10:29
Thomas Kramps,Knut ElbersIncludes cutting-edge methods and protocols.Provides step-by-step detail essential for reproducible results.Contains key notes and implementation advice from the experts.Includes supplementary materia作者: 充滿人 時(shí)間: 2025-3-22 13:17 作者: 健談 時(shí)間: 2025-3-22 18:55
Thomas Démoulins,Pavlos C. Englezou,Panagiota Milona,Nicolas Ruggli,Nicola Tirelli,Chantal Pichon,Céion and operational principles as well as its maintenance. The third part covers all relevant applications in which electrostatic accelerators are the preferred tool for accelerator-based investigations. Since some topics are common to all types of accelerators, .Electrostatic Accelerators. will als作者: 現(xiàn)暈光 時(shí)間: 2025-3-23 00:56 作者: CRUMB 時(shí)間: 2025-3-23 04:08
from a different internal geometry (1D for polymers vs. 2D for membranes) as well as from the fact that in condensed DNA phases the positional order is short ranged (liquid like) while it is quasi long ranged (smectic) in membrane assemblies. I will conclude by examining the interaction renormalizat作者: 含水層 時(shí)間: 2025-3-23 08:03
Susanne Rauch,Johannes Lutz,Aleksandra Kowalczyk,Thomas Schlake,Regina Heidenreich input parameters for the fault tree analysis in such cases, when risk of fire or explosion in the electrostatic precipitator must be taken into consideration. The paper represents the process of the creation of fault tree, the determination of fuzzy membership functions for the input probabilities,作者: Cumulus 時(shí)間: 2025-3-23 10:34 作者: medieval 時(shí)間: 2025-3-23 17:41 作者: Hamper 時(shí)間: 2025-3-23 21:04 作者: 脆弱么 時(shí)間: 2025-3-23 22:42 作者: Dorsal-Kyphosis 時(shí)間: 2025-3-24 03:44 作者: 亞麻制品 時(shí)間: 2025-3-24 09:57 作者: 擁護(hù)者 時(shí)間: 2025-3-24 13:18 作者: formula 時(shí)間: 2025-3-24 15:02 作者: liposuction 時(shí)間: 2025-3-24 20:23 作者: 反應(yīng) 時(shí)間: 2025-3-25 01:59 作者: 美色花錢 時(shí)間: 2025-3-25 03:38
Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells wittion protocol and the experience we have gathered with this method. The advantages of the transfection method presented here are: (1) easy adaptation to different cell types, (2) scalability from 10. to approximately 10. cells per shot, (3) high transfection efficiency (80–99 %), (4) homogenous prot作者: CRACK 時(shí)間: 2025-3-25 09:51
Enhanced Delivery of DNA or RNA Vaccines by Electroporationty, pulse length, pulse width and drug product formulation) majorly impact the efficiency of nucleic acid delivery. We provide an overview of DNA/RNA vaccination in the muscle of mice. Our results suggest that the technique is safe and effective and is highly applicable to a research setting as well作者: Sputum 時(shí)間: 2025-3-25 14:04
The European Regulatory Environment of RNA-Based Vaccineson whether RNA-based vaccines are directed against tumors or infectious disease, they are formally considered gene therapy products or not, respectively. Besides an overview on the current clinical use of mRNA vaccines in various therapeutic areas a detailed discussion of the current regulatory situ作者: 四指套 時(shí)間: 2025-3-25 16:31 作者: 退出可食用 時(shí)間: 2025-3-25 19:58 作者: Inflated 時(shí)間: 2025-3-26 03:54
ions in which electrostatic accelerators are the preferred tool for accelerator-based investigations. Since some topics are common to all types of accelerators, .Electrostatic Accelerators. will als978-3-642-06309-1978-3-540-27095-9Series ISSN 1611-1052 Series E-ISSN 2365-0877 作者: 減去 時(shí)間: 2025-3-26 05:53
ions in which electrostatic accelerators are the preferred tool for accelerator-based investigations. Since some topics are common to all types of accelerators, .Electrostatic Accelerators. will als978-3-642-06309-1978-3-540-27095-9Series ISSN 1611-1052 Series E-ISSN 2365-0877 作者: 葡萄糖 時(shí)間: 2025-3-26 11:03 作者: 租約 時(shí)間: 2025-3-26 15:45 作者: exclamation 時(shí)間: 2025-3-26 17:08
1064-3745 ation advice from the experts.Includes supplementary materia.This volume provides an overview of the field and practical hints for vaccinologists in academia and industry. Chapters provide protocols on self-replicating RNA vectors, non-replication mRNA vectors, adjuvantation and delivery, and precli作者: escalate 時(shí)間: 2025-3-26 23:57 作者: 針葉 時(shí)間: 2025-3-27 03:57 作者: meritorious 時(shí)間: 2025-3-27 06:10 作者: Expertise 時(shí)間: 2025-3-27 11:18 作者: Ruptured-Disk 時(shí)間: 2025-3-27 16:27 作者: insecticide 時(shí)間: 2025-3-27 18:35
Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergy bias that prevents TH2 sensitization. However, only mRNA vaccines fulfill the stringent safety requirements for vaccination of healthy children. In this chapter, we describe the generation of conventional as well as self-replicating mRNA vaccines and methods to test their prophylactic efficacy in animal models.作者: absolve 時(shí)間: 2025-3-28 00:32
Adjuvant-Enhanced mRNA Vaccinesntion over the earlier-established bacteria-, virus-, or cell-based vaccination approaches. Here, we present the experimental procedures employed in our laboratory to induce anticancer immune responses in different murine tumor models using IVT mRNA encoding for immune activation signals and antigens of interest.作者: 許可 時(shí)間: 2025-3-28 02:06
Considerations for Producing mRNA Vaccines for Clinical TrialsD) Application. For that, several preconditions concerning production, quality control, and assurance have to be fulfilled. Here, specific requirements related to mRNA vaccines are addressed on the basis of European standards.作者: stressors 時(shí)間: 2025-3-28 08:05 作者: 枕墊 時(shí)間: 2025-3-28 13:02 作者: 無彈性 時(shí)間: 2025-3-28 17:52 作者: 十字架 時(shí)間: 2025-3-28 22:22 作者: 喚醒 時(shí)間: 2025-3-29 01:16 作者: 骨 時(shí)間: 2025-3-29 05:46 作者: Conflagration 時(shí)間: 2025-3-29 09:56
Plant Expression of Trans-Encapsidated Viral Nanoparticle Vaccines with Animal RNA Repliconscapsidated with tobacco mosaic virus (TMV) coat protein can be fully assembled . cultures containing each component are inoculated together into tobacco leaves and the self-assembled hybrid nanoparticle vaccine is harvested 4 days later and purified with a simple PEG precipitation. The viral RNA del作者: 輪流 時(shí)間: 2025-3-29 15:04 作者: wangle 時(shí)間: 2025-3-29 17:37 作者: 哪有黃油 時(shí)間: 2025-3-29 23:32
Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergys has been recognized. mRNA and DNA vaccines have demonstrated their high potential for preventing allergic sensitization by inducing an immunological bias that prevents TH2 sensitization. However, only mRNA vaccines fulfill the stringent safety requirements for vaccination of healthy children. In t作者: Ordnance 時(shí)間: 2025-3-29 23:59 作者: Console 時(shí)間: 2025-3-30 07:26 作者: Allergic 時(shí)間: 2025-3-30 10:14
Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells wittypes. We have spent more than a decade to optimize and adapt this method, first for antigen-loading of dendritic cells (DCs), and subsequently for T cells, B cells, bulk PBMCs, and several cell lines. In this regard, antigens were introduced, processed, and presented in context of MHC class I and I作者: 開始發(fā)作 時(shí)間: 2025-3-30 13:33
Adjuvant-Enhanced mRNA Vaccinesent in its translational efficacy. Nowadays, mRNA-based vaccines represent a promising approach in the field of anticancer immunotherapy, gaining attention over the earlier-established bacteria-, virus-, or cell-based vaccination approaches. Here, we present the experimental procedures employed in o作者: fluffy 時(shí)間: 2025-3-30 17:54
